Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. (0HB0.L) Stock Overview
Explore Agios Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
2.2B
P/E Ratio
3.27
EPS (TTM)
$-6.43
ROE
0.59%
0HB0.L Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Agios Pharmaceuticals, Inc. (0HB0.L) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 70.04, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $44.55.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 3.27 and a market capitalization of 2.2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Company Profile
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Brian M. Goff
486
88 Sidney Street, Cambridge, MA
2018